IMC-002 is under clinical development by Suzhou Immunofoco Biotechnology and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IMC-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IMC-002 overview
IMC-002 is under investigation for the treatment of advanced CLDN18.2 positive solid tumors including gastric cancer, adenocarcinoma of the gastroesophageal junction, pancreatic cancer and metastatic ovarian cancer. It is administered parenterally through intravenous route. The therapeutic candidate comprises autologous T cells genetically manipulated to express chimeric antigen receptors (CAR) targeting cells expressing claudin 18.2.
Suzhou Immunofoco Biotechnology overview
Suzhou Immunofoco Biotechnology (Immunofoco) is a clinical-stage biotech company, focusing on immune cell drugs for patients with solid tumors. Immunofoco is headquartered in Shanghai, China.
For a complete picture of IMC-002’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
